Barcelona

• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS) Ended recruitment
  2022-502700-78-00 5 2023-09-01 Alopecia areata (AA)
• A Phase 1b study to evaluate the safety, pharmacokinetics, and anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously … Ended recruitment
  2023-504376-21-00 3 2023-08-28 pancreatic ductal adenocarcinoma
• A phase 3 study to Evaluate the Efficacy and Safety of HLX10 or placebo in Combination With Chemotherapy and Radiotherapy in Patients With L … Ended recruitment
  2024-515047-31-00 5 2023-08-28 Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) at stage
• LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended recruitment
  2022-501419-15-00 5 2023-08-23 Atrial Fibrillation
• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended recruitment
  2022-501176-26-00 5 2023-08-04 Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
• A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis Ended recruitment
  2024-510627-20-00 5 2023-07-28 Non-alcoholic Steatohepatitis (NASH) Cirrhosis
• A study of LOXO-783 in Patients with PIK3CA H1047R-Mutant Advanced Breast Cancer and Other Solid Tumors. Ended recruitment
  2023-509568-81-00 1 2023-07-27 Advanced Breast Cancer and Other Solid Tumors
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• Phase I study of AZD9592 in solid tumors Ended recruitment
  2022-501570-18-00 1 2023-07-18 Recurrent or metastatic Head and NeckSquamous Cell Carcinoma of the or
• A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended recruitment
  2022-501999-26-00 5 2023-07-12 Severe Hypertriglyceridemia (SHTG)
• Master Protocol of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobilia … Ended recruitment
  2022-502317-29-00 4 2023-07-12 Advanced Hepatobiliary Cancer
• A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com … Ended recruitment
  2022-501576-25-00 5 2023-07-07 Melanoma
• A long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation and a non-comparative transplante … Ended recruitment
  2022-502727-21-00 5 2023-07-03 Highly sensitised patients who have undergone kidney transplantation a
• A STUDY TO INVESTIGATE THE SAFETY AND EFFECTIVENESS OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY FOR PATIENTS WITH NON-SMALL CEL … Ended recruitment
  2022-502977-41-00 5 2023-06-23 Non-Small Cell Lung Cancer
• An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab … Ended recruitment
  2024-514016-26-00 4 2023-06-22 Multiple Myeloma
• A first-in-human dose escalation and expansion study with the SIRPα-directed monoclonal antibody BYON4228 alone and in combination with ritu … Ended recruitment
  2024-512390-27-00 1 2023-06-09 Relapsed/refractory CD20 positive B-cell Non-Hodgkin's Lymphoma (NHL)
• A study to test trimodulin in adult hospitalized patients with severe pneumonia Ended recruitment
  2022-501352-28-00 5 2023-06-07 Severe community-acquired pneumonia (sCAP)
• Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended recruitment
  2022-502145-10-00 5 2023-06-06 Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor
• Clinical study to investigate efficacy of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investiga … Ended recruitment
  2022-502065-23-00 4 2023-06-01 Refractory Metastatic Colorectal Cancer
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Ended recruitment
  2022-500700-22-00 5 2023-05-25 Active Systemic Lupus Erythematosus (SLE)
• A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Parti … Ended recruitment
  2023-509414-11-00 1 2023-05-24 Neoplasms
• PHASE II STUDY FOR PATIENTS WITH ADVANCED TRIPLE NEGATIVE OR METAPLASTIC HRPOSITIVE/HER2-NEGATIVE, PIK3CA/PTEN-ALTERED BREAST CANCER TREATED … Ended recruitment
  2024-512963-30-00 4 2023-05-24 Locally advanced or unresectable PIK3CA and/or PTENaltered metaplastic
• A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastroin … Ended recruitment
  2023-507522-16-00 5 2023-05-22 Metastatic Esophageal or Gastric Cancer

Showing 1,969–1,992 of 3,391 trials